Genzyme Licenses Gene Therapy Candidate For Parkinson’s Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
Ceregene deal worth up to $150 million plus future research reimbursements for the Phase II candidate.
You may also be interested in...
Introgen’s Advexin Doubles Survival In Some Head & Neck Cancer Patients
Firm plans end-of-June filing in U.S. and EU for p53 tumor suppressor in recurrent head and neck cancer.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.